Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Completes $120M Series F Financing

NEW YORK (GenomeWeb) – Invitae said on Monday that it completed a Series F financing round that raised $120 million.

The San Francisco-based genetic diagnostics firm will use the funds to continue building out its infrastructure and expand its global business, it said. New investors included the Broe Group, Decheng Capital, Deerfield Management, OrbiMed, Perceptive Advisors, Rock Springs Capital, and Wellington Management, and others.

Existing investors Casdin Capital, Genesys Capital, Genomic Health, Invitae Founder and CEO Randy Scott, Redmile Group, and Thomas McNerney & Partners also participated in the round.

Invitae was originally formed as a wholly owned subsidiary of Genomic Health in early 2012 and became an independent company later that year, combining with genetics firm Locus Development. It specializes in genetic diagnostics for hereditary disorders and currently offers a test with more than 200 genes for diagnosing genetic disorders associated with cancer, cardiology, neurology, and pediatrics.

Last December, the company raised $40 million in Series E financing. Invitae has raised a total of $207 million since its founding, it said.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.